Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced on July 31, 2026, that it has completed the second tranche of its previously announced private placement, issuing 6,250,000 units at a price of $0.40 per unit for aggregate gross proceeds of $2,500,000. Each unit consists of one common share and one common share purchase warrant, with each warrant entitling the holder to purchase an additional common share at an exercise price of $0.50 for a period of three years.
This completion brings the total gross proceeds raised under the offering to $2,948,130. The company has engaged Ventum Financial Corp. as a finder, paying cash commissions of $200,000 and issuing 500,000 warrants as compensation. The warrants include an acceleration clause that allows the company to shorten the expiry date if the volume-weighted average trading price of the common shares on the TSX Venture Exchange is at least $0.75 for 30 consecutive trading days.
The overall offering is for up to 8,000,000 units, aiming to raise up to $3,200,000. Ocumetics intends to close the remaining portion in subsequent tranches. The net proceeds from the offering are expected to fund the company's continuing first-in-human clinical trials, ongoing research and development, and general working capital. However, the actual allocation may vary based on future operations and opportunities.
The significance of this financing lies in its support for Ocumetics' pioneering work in ophthalmology. The company is developing a dynamic intraocular lens designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. This technology aims to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses, and without perceptible time lag.
Ocumetics is currently in the first-in-human early feasibility study phase, and the successful completion of this funding tranche is a critical step toward advancing these trials. The company's innovative approach could transform the field of vision correction, offering a potential alternative to traditional methods.
The securities issued in this tranche are subject to a hold period of four months and one day from the date of issuance, with finder warrants being non-transferable. The offering was subject to conditional approval from the TSX Venture Exchange, which has been obtained.
Ocumetics Technology Corp. is a Canadian research and product development company dedicated to developing advanced vision correction solutions. Through innovative research and development, the company aims to enhance the quality of life for patients by introducing state-of-the-art intraocular lenses and other vision-enhancing technologies.
For more information on this announcement, visit NewMediaWire.
